Navigation Links
Neurocrine Biosciences Reports Second Quarter 2013 Results
Date:7/25/2013

in early July 2013. The study is a placebo-controlled, double-blind, parallel-design, multiple-dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854 in tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study has incorporated a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in September 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the AIMS at the end of the six weeks of dosing. This study continues to enroll patients, and top-line data from this study is expected in the fourth quarter of 2013.

The Company plans to request an end of Phase II meeting with the FDA for NBI-98854 in tardive dyskinesia during the fourth quarter of 2013.

The Company is also in the process of initiating two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism. Both of these studies will be completed prior to the start of Phase III and will support the planned NDA filing.

Additionally, the Company has initiated preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Easter
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Neurocrine Biosciences Reports Third Quarter 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... (PRWEB) April 01, 2015 Proove ... Personalized Medicine , presented two scientific posters at the ... last week. The four-day event was hosted at the ... specialists dedicated to educating genetic and genomic professionals on ... Genetics and Insomnia: Study on the Role of DAT1 ...
(Date:4/1/2015)... , April 1, 2015  Among 1,050 U.S. consumers, ... oral cancer (68 percent) and only 36 percent reported ... check-up, according to findings from a survey ... leading innovator and developer of solutions that aid in ... The online survey polled 1,050 U.S. consumers on their ...
(Date:4/1/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, presented data on the company,s ... Experimental Biology conference in Boston, Massachusetts ... ideal extension of Organovo,s capabilities to 3D bioprint ... pharmaceutical research," said Keith Murphy , Chairman ...
(Date:4/1/2015)... DALLAS and NEW YORK ... Biopharmaceuticals, Inc. (NASDAQ:  PTBI), a biopharmaceutical company advancing ... today provided an overview of the Company,s 2014 ... highlighted achievements below demonstrate the progress the Company ... with multiple corporate partnerships for its MuGard programs, ...
Breaking Biology Technology:Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6
... April 3, 2008 Spherix,Incorporated (Nasdaq: SPEX ) ... December 31, 2007. The Company,s research and development costs,jumped ... with the launch of,the Company,s Phase 3 clinical trial ... April 2007. The trial is expected to last at ...
... Development, PLEASANTON, Calif., April 3, 2008 ... its new research facility,at the company,s global headquarters ... of consolidation of RMD,s West Coast,operations into one ... 500,employees, including 120 members of RMD,s research teams ...
... 3, 2008 Ratcliff, the,award-winning architecture, planning and ... 380,000-square-foot patient care tower,accompanied by a 767-stall parking ... Medical Center - Walnut Creek Campus. The Thomas ... recently broke ground will add,230 private and six ...
Cached Biology Technology:Spherix Reports 2007 Financial Results 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... to the puzzle of scaling how patterns stay in ... develops. In a new study appearing in Current Biology, Institute ... Danny Ben-Zvi of the Molecular Genetics Department have shown how ... the vein structure stays perfectly proportioned and their findings ...
... Male adult helminthomorph millipedes usually have one or ... into sexual appendages. These specialized gonopods are used as ... transfer sperm. New research published in BioMed Central,s open ... in detail at millipede development and the internal reorganization ...
... have published papers that associate chronic stress with chromosomal ... have discovered a mechanism that helps to explain the ... "We believe this paper is the first to propose ... stress, elevated adrenaline, could eventually cause DNA damage that ...
Cached Biology News:Scale models 2The secret life of millipedes 2At last, a reason why stress causes DNA damage 2
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
AK6 Antibody...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Biology Products: